Answers are grounded in this paper and cite their sources.
Introduction Over the last decade, there has been a significant increase in the scientific knowledge about cancer, which has accordingly led to the development and increase of interest in new medicines and therapeutic approaches with potential applications in oncology. Activity research and the identification of potential therapeutic and toxic effects of bexarotene-like structures underpin the development of new approaches to the treatment of a number of untreated diseases. This requires a further and in-depth study of the potential of newly synthesized compounds to produce active metabolites. Aim In view of the potential for dermal administration of bexarotene, the potential for toxic metabolism in the skin needs to be investigated. Materials and Methods For the purpose the OECD (Q) SAR Application Toolbox was used. It is a software application for evaluating the properties of chemicals based on their molecular structure. Results The application of the model for predicting metabolic changes makes it possible to assess the risk based on the chemical structure of the compounds. Conclusion The skin metabolic prediction of new hydrazones of third-generation retinoid bexarotene indicates that not one of them predicts binding to DNA or proteins.
No takes yet. Share an insight, caveat, or question.
Agova et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: